Drug Profile

MR 001 - Shenzhen Majory Biotechnology

Alternative Names: MR 001-Shenzhen Majory Biotechnology

Latest Information Update: 26 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Nov 2025 Shenzhen Majory Biotechnology plans phase I/II in Triple-negative breast cancer (Late-staged disease, Metastatic disease, Second line therapy or greater and Recurrent) in China in December 2025 (IV) (NCT07208149)
19 Nov 2025 Preclinical trials in Cancer in China (Parenteral) prior to November 2025
19 Nov 2025 Shenzhen Majory Biotechnology plans a phase Ib/IIa trial for Adenocarcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (IV, Infusion) (NCT07235202)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com